Roche launches diagnostic test panels to detect respiratory illnesses
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Roche launches diagnostic test panels to detect respiratory illnesses

22 Sep 2021 (Last Updated September 22nd, 2021 13:00)

The three new respiratory test panels can be run together or alone using one patient sample.

Roche launches diagnostic test panels to detect respiratory illnesses
The test panels run on cobas 6800/8800 Systems and can detect and differentiate common respiratory pathogens at the same time. Credit: F Hoffmann-La Roche.

Roche has launched three molecular polymerase chain reaction (PCR) diagnostic test panels to detect and differentiate common respiratory pathogens at the same time.

The common respiratory illnesses include influenza A, influenza B and respiratory syncytial virus (RSV); adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV); and parainfluenza 1, 2, 3 and 4.

The new respiratory test panels, designed to test influenza and other common respiratory illnesses, can be run together or alone using one nasopharyngeal swab specimen.

They use a real-time PCR nucleic acid amplification method to detect specific DNA sequences obtained after extraction.

This helps to achieve quick detection and specific measurement of genes from microorganisms that are associated with infectious diseases, cancer and genetic abnormalities.

Roche stated that the flexible syndromic-style test panel provides clinicians with actionable insights sooner when compared to conventional methods and also reduces unnecessary testing.

In addition to improving patient care, the test helps with proper hospital bed management and infection control.

Roche Diagnostics CEO Thomas Schinecker said: “Our latest set of syndromic respiratory solutions allows clinicians to choose the appropriate tests based on the healthcare setting, season and patient needs.

“By testing only what is medically relevant and necessary, we enable targeted therapy, avoid misuse of antibiotics and reduce unnecessary intervention.”

The molecular PCR diagnostic test panels run on the cobas omni–Utility Channel, cobas 6800/8800 Systems.

Furthermore, the company stated that it aims to expand the availability of these tests beyond CE markets in the future.

Earlier this month, Roche entered a definitive agreement with TIB Molbiol Group to acquire all of the company’s outstanding shares to bolster its molecular diagnostics portfolio.